In a new report released Thursday (Oct. 25), the White House Council of Economic Advisers touts FDA’s efforts to drive down drug prices by ramping up drug approvals and increasing competition on the marketplace, pointing to both generic and brand drug approvals. While FDA Commissioner Scott Gottlieb and experts consistently highlight the need for more generic drugs to enter the market to achieve HHS’ drug competition and pricing goals, CEA also argues that there should be focus on new drug...